Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661126 | 0.77 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9243660 | 0.74 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| Dipyridyl SCHEMBL28135789 | 0.73 | KDM4E (0.64) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5327985 | 0.72 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL11786505 | 0.71 | METAP2 (0.43) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1082873 | 0.71 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL3803910 | 0.71 | TP53 (0.49) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18107153 | 0.70 | TLR8 (0.41) | CYP1A2KDM4ELMNA | |
| SCHEMBL8619864 | 0.70 | PDPK1 (0.44) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27883130 | 0.70 | TP53 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098536-A1 | Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use | C-A-I-R- BIOSCIENCES GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-1909102-A1 | Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38mapk antibodies, kits and their use | c-a-i-r biosciences GmbH (DE) | 2008-04-09 | — | — | EP | disclosed |
| US-7041686-B2 | Substituted imidazoles useful in the treatment of inflammatory diseases | ORTHO MCNEIL PHARMACEUTICAL, CORP. | 2006-05-09 | — | — | US | disclosed |
| CN-1211381-C | Substituted imidazoles useful in treatment of inflammatory diseases | ORTHO MCNEIL CORP INC (US) | 2005-07-20 | — | — | CN | disclosed |
| EP-1337526-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040214816-A1 | Substituted imidazoles useful in the treatment of inflammatory diseases | ORTHO MCNEIL PHARMACEUTICAL, CORP. | 2004-10-28 | — | — | US | disclosed |
| EP-1060181-B1 | SUBSTITUTED PYRROLOBENZIMIDAZOLES FOR TREATING INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1337526-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1028954-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1178981-B1 | SUBSTITUTED 3-PYRIDYL-4-ARYLPYRROLES, AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ORTHO MCNEIL PHARM INC (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| CN-1253558-A | Substituted imidazoles useful in treatment of inflammatory diseases | ORTHO MCNEIL CORP INC (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0994858-A1 | 2-SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6040320-A | ANTIINFLAMMATORY AGENT FOR TREATING DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES, SUCH AS RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISEASE, SEPTIC SHOCK, OSTEOPOROSIS, AND OSTEOARTHRITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999058128-A1 | INHIBITION OF PROTEIN KINASES WITH PIRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999043680-A1 | SUBSTITUTED PYRROLOBENZIMIDAZOLES FOR TREATING INFLAMMATORY DISEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999003837-A1 | 2-SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998047899-A1 | SUBSTITUTED PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214816-A1 | Substituted imidazoles useful in the treatment of inflammatory diseases | IL1B, IL1A, TNF | CYP1A2 85/4885CYP2D6 235/4885CYP19A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.